Combination therapy with lysin CF-301 and antibiotic is superior to antibiotic alone for treating methicillin-resistant staphylococcus aureus-induced murine bacteremia

Journal of Infectious Diseases

Volumn 209, Issue 9, 2014, Pages 1469-1478

  Schuch, Raymond ^a   Lee, Han M ^a   Schneider, Brent C ^a   Sauve, Karen L ^a   Law, Christina ^a   Khan, Babar K ^a   Rotolo, Jimmy A ^a   Horiuchi, Yuki ^a   Couto, Daniel E ^a   Raz, Assaf ^b   Fischetti, Vincent A ^b   Huang, David B ^a   Nowinski, Robert C ^a   Wittekind, Michael ^a  

^a Contra Fect Corporation ^*  (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

bacteremia; daptomycin; lysin; MRSA; Staphylococcus aureus; vancomycin

Indexed keywords

BACTEREMIA; DAPTOMYCIN; LYSIN; MRSA; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

AMINO ACID SEQUENCE; ANIMALS; ANTI-BACTERIAL AGENTS; BACTEREMIA; BIOFILMS; DRUG SYNERGISM; FEMALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUCOPROTEINS; PROPHAGES; STAPHYLOCOCCAL INFECTIONS; VIRAL PROTEINS;

EID: 84898837304     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jit637     Document Type: Article

References (45)

1. Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007; 298:1763-71
2. Landrum ML, Neumann C, Cook C, et al. Epidemiology of Staphylococcus aureus blood and skin and soft tissue infections in the US military health system, 2005-2010. JAMA 2012; 308:50-9
3. Brink AJ. Does resistance in severe infections caused by methicillin-resistant Staphylococcus aureus give you the 'creeps'? Cur Opin Crit Care 2012; 18:451-9
4. Ben-David D, Novikov I, Mermel LA. Are there differences in hospital cost between patients with nosocomial methicillin-resistant Staphylococcus aureus bloodstream infection and those with methicillin-susceptible S. aureus bloodstream infection? Infect Control Hosp Epidemiol 2009; 30:453-60
5. Fischetti VA. Bacteriophage lysins as effective antibacterials. Curr Opin Microbiol 2008; 11:393-400
6. Fenton M, Ross P, McAuliffe O, O'Mahony J, Coffey A. Recombinant bacteriophage lysins as antibacterials. Bioeng Bugs 2010; 1:9-16
7. Nelson D, Loomis L, Fischetti VA. Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme. Proc Natl Acad Sci U S A 2001; 98:4107-12
8. Witzenrath M, Schmeck B, Doehn JM, et al. Systemic use of the endolysin Cpl-1 rescues mice with fatal pneumococcal pneumonia. Crit Care Med 2009; 37:642-9
9. McCullers JA, Karlstrom A, Iverson AR, Loeffler JM, Fischetti VA. Novel strategy to prevent otitis media cauesed by colonizing Streptococcus pneumoniae. PLoS Pathog 2007; 3:0001-3
10. Pastagia M, Euler C, Chahales P, Fuentes-Duculan J, Krueger JG, Fischetti VA. A novel chimeric lysin shows superiority to mupirocin for skin decolonization of methicillin-resistant and-sensitive Staphylococcus aureus strains. Antimicrob Agents Chemother 2011; 55:738-44
11. Loeffler JM, Djurkovic S, Fischetti VA. Phage lytic enzyme Cpl-1 as a novel antimicrobial for pneumococcal bacteremia. Infect Immun 2003; 71:6199-204
12. Entenza JM, Loeffler JM, Grandgirard D, Fischetti VA, Moreillon P. Therapeutic effects of bacteriophage Cpl-1 lysin against Streptococcus pneumoniae endocarditis in rats. Antimicrob Agents Chemother 2005; 49:4789-92
13. Grandgirard D, Loeffler JM, Fischetti VA, Leib SL. Phage lytic enzyme Cpl-1 for antibacterial therapy in experimental pneumococcal meningitis. J Infect Dis 2008; 197:1519-22
14. Blaser M. Stop killing beneficial bacteria. Nature 2011; 476:393-4
15. Willing BP, Russell SL, Finlay BB. Shifting the balance: Antibiotic effects on host-microbiota mutualism. Nature Rev Microbiol 2011; 9:233-43
16. Gilmer DB, Schmitz JE, Euler CW, Fischetti VA. Novel bacteriophage lysin with broad lytic activity protects against mixed infection by Streptococcus pyogenes and methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2013; 57:2743-50
17. Rossi P, Aramini JM, Xiao R, et al. Structural elucidation of the Cys-His-Glu-Asn proteolytic relay in the secreted CHAP domain enzyme from the human pathogen Staphylococcus saprophyticus. Proteins 2009; 74:515-9
18. Zhang Y. I-TASSER server for protein 3D structure prediction. BMC Bioinformatics 2008; 9:40
19. Schrodinger, LLC. Portland, OR USA. The PyMOL molecular graphics system, Version 1.6.0.0, 2013
20. Bateman A, Rawlings ND. The CHAP domain: A large family of amidases including GSP amidase and peptidoglycan hydrolases. Trends Biochem Sci 2003; 28:234-7
21. Whisstock JC, Lesk AM. SH3 domains in prokaryotes. Trends Biochem Sci 1999; 24:132-3
22. Fenton M, Casey PG, Hill C, et al. The truncated phage lysin CHAP(k) eliminates Staphylococcus aureus in the nares of mice. Bioeng Bugs 2010; 1:404-7
23. Manoharadas S, Witte A, Blasi U. Antimicrobial activity of a chimeric enzybiotic towards Staphylococcus aureus. J Biotechnol 2009; 139:118-23
24. O'Flaherty S, Coffey A, Meaney W, Fitzgerald GF, Ross RP. The recombinant phage lysin LysK has a broad spectrum of lytic activity against clinically relevant staphylococci, including methicillin-resistant Staphylococcus aureus. J Bacteriol 2005; 187:7161-4
25. Clinical and Laboratory Standards Institute. M07-A9. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 8th ed.Wayne, PA: CLSI, 2012
26. Clinical and Laboratory Standards Institute. M26-A. Methods for determining bactericidal activity of antimicrobial agents; approved guideline. Wayne, PA: CLSI, 1999
27. Mueller M, de la Pena A, Derendorf H. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: Kill curves versus MIC. Antimicrob Agents Chemother 2004; 48:369-77
28. Moody J. Synergy testing: Broth microdilution checkerboard and broth macrodilution methods. In: Garcia LS, ed. Clinical microbiology procedures handbook. Vol. 2. Washington, DC: ASM Press, 2010: 5.12.1-23
29. Tallarida RJ. Revisiting the isobole and related quantitative methods for assessing drug synergism. J Pharmacol Exp Ther 2012; 342:2-8
30. Abad CL, Kumar A, Safdar N. Antimicrobial therapy of sepsis and septic shock-when are two drugs better than one? Crit Care Clin 2011; 27:e1-27
31. Cottarel G, Wierzbowski J. Combination drugs, an emerging option for antibacterial therapy. Trends Biotechnol 2007; 25:547-55
32. Fischbach MA. Combination therapies for combating antimicrobial resistance. Curr Opin Microbiol 2011; 14:519-23
33. Loeffler JM, Nelson D, Fischetti VA. Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase. Science 2001; 294:2170-2
34. Costerton JW. Bacterial biofilms: A common cause of persistent infections. Science 1999; 284:1318-22
35. Kiedrowski MR, Horswill AR. New approaches for treating staphylococcal biofilm infections. Ann NY Acad Sci 2011; 1241:104-21
36. Domenech M, Garcia E, Moscoso M. In vitro destruction of Streptococcus pneumoniae biofilms with bacterial and phage peptidoglycan hydrolases. Antimicrob Agents Chemother 2011; 55:4144-8
37. Meng X, Shi Y, Ji W, et al. Application of a bacteriophage lysin to disrupt biofilms formed by the animal pathogen Streptococcus suis. Appl Environ Microb 2011; 77:8272-9
38. Rashel M, Uchiyama J, Ujihara T, et al. Efficient elimination of multidrug-resistant Staphylococcus aureus by cloned lysin derived from bacteriophage phi MR11. J Infect Dis 2007; 196:1237-47
39. Daniel A, Euler C, Collin M, Chahales P, Gorelick KJ, Fischetti VA. Synergism between a novel chimeric lysin and oxacillin protects against infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2010; 54:1603-12
40. Kokai-Kun JF, Chanturiya T, Mond JJ. Lysostaphin as a treatment for systemic Staphylococcus aureus infection in a mouse model. J Antimicrob Chemother 2007; 60:1051-9
41. Dhand A, Bayer AS, Pogliano J, et al. Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: Role of enhanced daptomycin binding. Clin Infect Dis 2011; 53:158-63
42. Matias VR, Beveridge TJ. Cryo-electron microscopy of cell division in Staphylococcus aureus reveals a mid-zone between nascent cross walls. Mol Microbiol 2007; 64:195-206
43. Schuch R, Nelson D, Fischetti V. A bacteriolytic agent that detects and kills Bacillus anthracis. Nature 2002; 418:884-9
44. Crandon JL, Kuti JL, Nicolau DP. Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillinresistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model. Antimicrob Agents Chemother 2010; 54:5115-9
45. LaPlante KL, Leonard SN, Andes DR, Craig WA, Rybak MJ. Activities of clindamycin, daptomycin, doxycycline, linezolid, trimethoprimsulfamethoxazole, and vancomycin against community-Associated methicillin-resistant Staphylococcus aureus with inducible clindamycin resistance in murine thigh infection and in vitro pharmacodynamic models. Antimicrob Agents Chemother 2008; 52:2156-62.